Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 3Hematologic Neoplasms 3Respiratory Distress Syndrome 1Pneumonia 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1Graft vs Host Disease 1Burkitt Lymphoma 1

Interventions

tocilizumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Distress Syndrome × tocilizumab × Other hematologic neoplasm × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡